SETD2 and rheumatoid arthritis: The current study demonstrated that TSPJ may regulate the VEGF or HIF-1 signaling pathways by inhibiting two targets, STAT 3 and SRC, thus inhibiting inflammation and angiogenesis, which will provide a new strategy for the treatment of RA.